All In Biotech

Drug Trial Radar · NCT04660812

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

227

Actual

Start

May 10, 2021

Primary completion

Sep 5, 2025

Study completion Sep 5, 2025

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • AB680Drug

    AB680 is a cluster of differentiated CD73 Inhibitor

  • EtrumadenantDrug

    Etrumadenant is a dual adenosine receptor (A2aR and A2bR) antagonist

  • ZimberelimabDrug

    Zimberelimab is a fully human anti-PD-1 monoclonal antibody

  • BevacizumabDrug

    Bevacizumab is administered as part of standard chemotherapy regimen

  • m-FOLFOX-6 regimenDrug

    mFOLFOX-6 regimen is administered as part of standard chemotherapy regimen

  • RegorafenibDrug

    Regorafenib is administered as part of standard chemotherapy regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A and B - Progression-free Survival (PFS)Time frame: From randomization until death from any cause (up to approximately 3-7 years)
  2. Cohort C - Objective Response Rate (ORR)Time frame: From randomization until death from any cause (up to approximately 3-7 years)
  3. Number of Participants With Treatment-emergent Adverse EventsTime frame: Up to approximately 10 Months

Locations

44 sites in 6 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Research Center Inc

    Tucson, Arizona

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • UCLA Hematology Oncology

    Santa Monica, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • Winship Cancer Institute at Emory University

    Atlanta, Georgia

  • Ochsner Medical Center (OMC)

    New Orleans, Louisiana

  • American Oncology Partners of Maryland PA

    Bethesda, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Comprehensive Cancer Centers Of Nevada

    Las Vegas, Nevada

  • NYU Langone Medical Center - NYU Medical Oncology Associates

    New York, New York

  • New York-Presbyterian Hospital-Columbia University Medical Center

    New York, New York

  • Prisma Health-Upstate

    Greenville, South Carolina

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Wisconsin School of Medicine

    Madison, Wisconsin

  • Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Hopital Hotel Dieu

    Nantes, France

  • Hopital Saint Antoine

    Paris, France

  • Groupe Hospitalier Pitie-Salpetriere-Centre De Recherche et de Medecine de l'Obesite

    Paris, France

  • CHU la Miletrie

    Poitiers, France

  • IRCCS - Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

    Castellana Grotte, Italy

  • Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica

    Florence, Italy

  • Azienda Ospedaliera Niguarda Ca' Granda

    Milan, Italy

  • Instituto Europeo di Oncologia

    Milan, Italy

  • Istituto Clinico Humanitas IRCCS

    Rozzano, Italy

  • Universita di Siena - Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte

    Siena, Italy

  • Chonnam National University Hwasun Hospital

    Hwasun, South Korea

  • Seoul National University Bundang Hospital

    Seoul, South Korea

  • Seoul National University Hospital (SNUH)

    Seoul, South Korea

  • Severance Hospital | Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center | University of Ulsan College of Medicine

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Kyungpook National University Chilgok Hospital

    Seoul, South Korea

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Complejo Hospitalario de Orense

    Ourense, Spain

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.